Abstract
Atrial fibrillation in patients with rheumatic valvular heart disease results in significant morbidity and possibly mortality. The recent advances in treatment options for non-rheumatic atrial fibrillation have widened its scope of management. These treatment modalities have not been extensively validated in rheumatic valvular heart disease. A review and comparison of the available data in atrial fibrillation and rheumatic valvular heart disease vis-à-vis non-rheumatic atrial fibrillation is presented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
